People already infected with COVID-19 are protected from reinfection, as are the best people who get the COVID-19 vaccine, according to a survey of 20,000 medical workers in the UK. The largest study in the world
Public Health England tested two matching volunteer groups between June and November – 6,000 health workers who previously contracted the coronavirus and 14,000 who had never been infected.
A comparison of the two infection groups, described in a preliminary study published Thursday, found that previous infections provided at least 83 percent protection against recurrent infections, providing protection against symptomatic COVID-19. That’s 94 percent better, matching the numbers for the most effective Covid-19 vaccine.
Susan Hopkins, a senior medical advisor at PHE, said she was “greatly encouraged” by finding that the infection was powerful – although not yet complete – at least to prevent re-infection. Five months
“Natural infections look as good as vaccines, which is good news for the population,” she said.
Although the study cannot provide information on a possible prevention beyond five months. But Professor Hopkins is optimistic that the study will last “more than a few months people had guessed” in the early stages of last year’s outbreak.
“It will provide a level of immunity in the community that will reduce transmission,” she said.
During the study, 44 of the 6,000 previously infected cohort tested positive for at least 3 months, indicating they had been But since genome analysis cannot confirm that different viruses are responsible for the two infections, it is not considered a proven infection. The same virus may be incubated for a long time within the same person, although researchers think most are less likely.
Eleanor Riley, a professor of virology at the University of Edinburgh, said the study data also suggested that people who had recovered from COVID-19 were less likely to unknowingly transmit the virus to others as the infection seemed naturally. It will help prevent approximately 75 percent of recurrent infections without symptoms. “This is good news in terms of long-term outbreak trends,” she said.
Still, Professor Hopkins urges people to “don’t misunderstand these early findings.”
“If you believe you already have this disease and are protected, you can be confident that you are highly unlikely to have a serious infection. But there is still a risk that you will be infected and spread it to others, ”she said.
The cutoff for the preliminary analysis in late November came too early for researchers to determine how the first vaccine was approved for use in the UK in December in the study group.
Researchers were not yet able to assess the impact of the new and more contagious B.1.7 variant on the rate of recurrent infection. PHE aims to expand the research program over the next three months to include 100,000 health workers and Consider both questions.